相似文献
1
Resistance to EGFR-targeted therapy: a family affair.
Cancer Cell. 2011 Oct 18;20(4):423-5. doi: 10.1016/j.ccr.2011.10.006.
2
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Clin Cancer Res. 2006 Jul 1;12(13):4103-11. doi: 10.1158/1078-0432.CCR-05-2404.
3
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442.
4
Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer.
BMC Cancer. 2014 Nov 22;14:863. doi: 10.1186/1471-2407-14-863.
5
The ErbB/HER family of protein-tyrosine kinases and cancer.
Pharmacol Res. 2014 Jan;79:34-74. doi: 10.1016/j.phrs.2013.11.002. Epub 2013 Nov 20.
6
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Pharmacol Res. 2019 Jan;139:395-411. doi: 10.1016/j.phrs.2018.11.014. Epub 2018 Nov 27.
7
Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI.
Oncogenesis. 2019 Sep 30;8(10):54. doi: 10.1038/s41389-019-0164-9.
8
Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2.
Hum Pathol. 1998 Aug;29(8):771-7. doi: 10.1016/s0046-8177(98)90444-0.
9
Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery.
Eur J Cancer. 2002 May;38(8):1065-71. doi: 10.1016/s0959-8049(02)00004-7.
10
Impact of EGFR and EGFR ligand expression on treatment response in patients with metastatic colorectal cancer.
Oncol Lett. 2021 Jun;21(6):448. doi: 10.3892/ol.2021.12709. Epub 2021 Apr 7.
引用本文的文献
1
ERBB3-related gene PBX1 is associated with prognosis in patients with HER2-positive breast cancer.
BMC Genom Data. 2025 Jan 10;26(1):2. doi: 10.1186/s12863-024-01292-0.
2
HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.
Cells. 2023 Oct 25;12(21):2517. doi: 10.3390/cells12212517.
3
First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.
Invest New Drugs. 2022 Jun;40(3):586-595. doi: 10.1007/s10637-022-01217-7. Epub 2022 Feb 3.
4
Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
J Exp Clin Cancer Res. 2021 Oct 18;40(1):328. doi: 10.1186/s13046-021-02130-2.
5
NOTCH1 signaling promotes protein stability of HER3 through the AKT pathway in squamous cell carcinoma of head and neck.
Oncogenesis. 2021 Aug 31;10(8):59. doi: 10.1038/s41389-021-00348-5.
6
[Bacterial expression of 183-227aa region of HER3 extracellular domain I and preparation and identification of its polyclonal antibodies].
Nan Fang Yi Ke Da Xue Xue Bao. 2020 Jun 30;40(6):806-813. doi: 10.12122/j.issn.1673-4254.2020.06.06.
7
Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.
Breast Cancer Res. 2020 May 15;22(1):48. doi: 10.1186/s13058-020-01280-z.
8
Optimizing Advances in Nanoparticle Delivery for Cancer Immunotherapy.
Adv Drug Deliv Rev. 2019 Apr;144:3-15. doi: 10.1016/j.addr.2019.07.009. Epub 2019 Jul 19.
9
Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma.
Front Oncol. 2018 Oct 5;8:432. doi: 10.3389/fonc.2018.00432. eCollection 2018.
10
HER3 signaling and targeted therapy in cancer.
Oncol Rev. 2018 May 16;12(1):355. doi: 10.4081/oncol.2018.355. eCollection 2018 Jan 30.
本文引用的文献
1
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer.
Cancer Discov. 2011 Nov;1(6):508-23. doi: 10.1158/2159-8290.CD-11-0109. Epub 2011 Sep 2.
2
Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab.
Sci Transl Med. 2011 Sep 7;3(99):99ra86. doi: 10.1126/scitranslmed.3002442.
3
The mutational landscape of head and neck squamous cell carcinoma.
Science. 2011 Aug 26;333(6046):1157-60. doi: 10.1126/science.1208130. Epub 2011 Jul 28.
4
Dual kinase inhibition of EGFR and HER2 overcomes resistance to cetuximab in a novel in vivo model of acquired cetuximab resistance.
Clin Cancer Res. 2011 Sep 15;17(18):5935-44. doi: 10.1158/1078-0432.CCR-11-0370. Epub 2011 Jul 26.
5
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
Clin Cancer Res. 2008 Oct 1;14(19):6277-83. doi: 10.1158/1078-0432.CCR-08-0482.
6
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: a fluorescent in situ hybridization study.
Clin Cancer Res. 2008 Sep 15;14(18):5869-76. doi: 10.1158/1078-0432.CCR-08-0449.
7
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network.
Clin Cancer Res. 2007 Aug 15;13(16):4909-19. doi: 10.1158/1078-0432.CCR-07-0701.
8
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
J Clin Oncol. 2007 Aug 1;25(22):3230-7. doi: 10.1200/JCO.2006.10.5437.
9
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Science. 2007 May 18;316(5827):1039-43. doi: 10.1126/science.1141478. Epub 2007 Apr 26.
10
Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo.
Mol Cancer Res. 2003 Jan;1(3):165-75.
Zotero 插件